Arcturus Therapeutics In... (ARCT)
Arcturus Therapeutics Statistics
Share Statistics
Arcturus Therapeutics has 27.12M shares outstanding. The number of shares has increased by 0.7% in one year.
| Shares Outstanding | 27.12M |
| Shares Change (YoY) | 0.7% |
| Shares Change (QoQ) | 0.12% |
| Owned by Institutions (%) | 98.46% |
| Shares Floating | 24.37M |
| Failed to Deliver (FTD) Shares | 58 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 4.65M, so 17.14% of the outstanding shares have been sold short.
| Short Interest | 4.65M |
| Short % of Shares Out | 17.14% |
| Short % of Float | 26.85% |
| Short Ratio (days to cover) | 13.12 |
Valuation Ratios
The PE ratio is -5.66 and the forward PE ratio is -3.3. Arcturus Therapeutics's PEG ratio is -0.03.
| PE Ratio | -5.66 |
| Forward PE | -3.3 |
| PS Ratio | 3.01 |
| Forward PS | 0.5 |
| PB Ratio | 1.9 |
| P/FCF Ratio | -7.59 |
| PEG Ratio | -0.03 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Arcturus Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.67, with a Debt / Equity ratio of 0.1.
| Current Ratio | 4.67 |
| Quick Ratio | 4.67 |
| Debt / Equity | 0.1 |
| Debt / EBITDA | -0.32 |
| Debt / FCF | -0.41 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $875.34K |
| Profits Per Employee | $-465.18K |
| Employee Count | 174 |
| Asset Turnover | 0.44 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -4K |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -50.75% in the last 52 weeks. The beta is 3.41, so Arcturus Therapeutics's price volatility has been higher than the market average.
| Beta | 3.41 |
| 52-Week Price Change | -50.75% |
| 50-Day Moving Average | 13.29 |
| 200-Day Moving Average | 17.96 |
| Relative Strength Index (RSI) | 59.91 |
| Average Volume (20 Days) | 442.65K |
Income Statement
In the last 12 months, Arcturus Therapeutics had revenue of 152.31M and earned -80.94M in profits. Earnings per share was -3.
| Revenue | 152.31M |
| Gross Profit | 152.31M |
| Operating Income | -95.67M |
| Net Income | -80.94M |
| EBITDA | -77.4M |
| EBIT | -80.94M |
| Earnings Per Share (EPS) | -3 |
Balance Sheet
The company has 237.03M in cash and 25M in debt, giving a net cash position of 212.03M.
| Cash & Cash Equivalents | 237.03M |
| Total Debt | 25M |
| Net Cash | 212.03M |
| Retained Earnings | -448.81M |
| Total Assets | 344.07M |
| Working Capital | 240.49M |
Cash Flow
In the last 12 months, operating cash flow was -59.75M and capital expenditures -648K, giving a free cash flow of -60.4M.
| Operating Cash Flow | -59.75M |
| Capital Expenditures | -648K |
| Free Cash Flow | -60.4M |
| FCF Per Share | -2.24 |
Margins
Gross margin is 100%, with operating and profit margins of -62.81% and -53.14%.
| Gross Margin | 100% |
| Operating Margin | -62.81% |
| Pretax Margin | -53.14% |
| Profit Margin | -53.14% |
| EBITDA Margin | -50.82% |
| EBIT Margin | -62.81% |
| FCF Margin | -39.65% |
Dividends & Yields
ARCT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for ARCT is $60, which is 365.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $60 |
| Price Target Difference | 365.5% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Stock Splits
The last stock split was on Nov 16, 2017. It was a backward split with a ratio of 1:7.
| Last Split Date | Nov 16, 2017 |
| Split Type | backward |
| Split Ratio | 1:7 |
Scores
| Altman Z-Score | 0.63 |
| Piotroski F-Score | 3 |